Crossject Société Anonyme (74C.F)

2.1100 +0.1100 (+5.50%) As of 08:08AM CEST. Market open.

Crossject Société Anonyme

6 Rue Pauline Kergomard
Dijon 21000
France
33 3 80 54 98 50
https://www.crossject.com

Sector(s): Healthcare
Industry: Medical Instruments & Supplies
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Patrick Alexandre	Co-Founder, CEO & Chairman of the Executive Board	N/A	N/A	N/A
Dr. Isabelle Liebschütz	Chief Quality & Regulatory Officer and Member of Executive Board	N/A	N/A	N/A
Mr. Henri de Parseval	COO of Engineering & Industry and Member of Executive Board	N/A	N/A	N/A
Mr. Olivier Giré	COO of Specialty Pharma & Member of Executive Board	N/A	N/A	N/A

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, a needle-free device for patient-side management disorders self-injectables. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. The company was founded in 2001 and is based in Dijon, France.

Corporate governance

Crossject Société Anonyme’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.